News

REUTERS — Mar 18 — Medicis Pharmaceutical Corp’s biggest product Solodyn will face generic competition sooner than expected after U.S. health regulators denied a petition from the company to stop copy-cat versions of the acne drug from entering the market. Teva Pharmaceutical Industries Ltd, the world’s largest generic drugmaker, said it would launch a generic version of Solodyn immediately, and that shipment of the product had already started. READ FULL ARTICLE @ REUTERS
CAAH Summary: Drug company Medicis, the manufacturers of Solodyn, submitted a petition to protect their patent for the medication. This petition was denied, allowing drug maker Teva Pharmaceutical Industries to market its generic version of Solodyn. The article, intended for the “Business & Finance” reader, did not detail what Solodyn is, reporting only that it is an acne drug. To shed a bit of light for those who may not know of the medication, Solodyn is an antibiotic tablet prescribed to reduce the number of acne lesions in patients 12 years of age and older. with the patent petition denied, other companies legally have the right to manufacture and sell Solodyn. Teva, the largest generic drug maker in the world, got approval for its generic version of Solodyn and released it immediately after the announcement. Shipment of the lower-cost alternative has already begun.

Image credit: Walter Watzpatzkowski

Incoming search terms for the article:

• cost of solodyn acne

Related posts:

1. Acne Scars Study – Isolagen Reports Positive Results From Phase II/III
2. Are Claims About Beauty Creams Only Skin Deep?
3. The Voluntary Recall of Accutane